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Abstract: Cancers attributable to human papillomavirus (HPV) place a huge burden on the health
of both men and women. The current commercial vaccines are genotype specific and provide little
therapeutic benefit to patients with existing HPV infections. Identifying the conformational epitopes
on the virus capsid supports the development of improved recombinant vaccines to maximize
long-term protection against multiple types of HPV. Fragments of antibody (Fab) digested from the
neutralizing monoclonal antibodies H16.V5 (V5) and H16.U4 (U4) were bound to HPV16 capsids
and the structures of the two virus-Fab complexes were solved to near atomic resolution using
cryo-electron microscopy. The structures reveal virus conformational changes, the Fab-binding
mode to the capsid, the residues comprising the epitope and indicate a potential interaction of U4
with the minor structural protein, L2. Competition enzyme-linked immunosorbent assay (ELISA)
showed V5 outcompetes U4 when added sequentially, demonstrating a steric interference even
though the footprints do not overlap. Combined with our previously reported immunological and
structural results, we propose that the virus may initiate host entry through an interaction between
the icosahedral five-fold vertex of the capsid and receptors on the host cell. The highly detailed
epitopes identified for the two antibodies provide a framework for continuing biochemical, genetic
and biophysical studies.
Keywords: human papillomavirus; cryo-electron Microscopy (cryo-EM); conformational epitope;
antibody neutralization; U4 and V5; competition; steric clash; complex; virus; fab
1. Introduction
Human papillomavirus (HPV) is a non-enveloped DNA virus capable of causing anogenital warts
and associated with cancers of the cervix, vagina, vulva, anus, penis, oral cavity and oropharynx
(level II) [1–3]. Cancers attributed to HPV place a significant burden on the health of both men
and women with cervical cancer presenting as the most common disease [4–6], although rates of
oropharyngeal squamous cell carcinomas have risen disproportionately in men (7.6 per 100,000 persons
compared to 1.7 in females) [7]. Commercial vaccines targeting the major capsid protein, L1, have been
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applied successfully to protect against high-risk HPV—for example, a new 9-valent vaccine for
HPV was developed recently that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 [3].
However, the efficacy of vaccines is still genotype specific and vaccines provide little therapeutic
benefit against existing infection [8]. Understanding the antigenic nature of the HPV capsid offers
an opportunity to discover structural features that are crucial to capsid integrity and conserved
across species. Identifying neutralization-sensitive epitopes on the surface of the capsid adds to
ongoing development of improved recombinant vaccines that maximize long-term antibody-mediated
protection against multiple HPV Types [9–12].
Among more than 170 genotypes, HPV16 is the most prevalent high-risk type of HPV and has
been a primary target for the development of prophylactic vaccines [13–15]. The infectious HPV16
has a T = 7 icosahedral capsid (55 to 60 nm in diameter) comprised of 72 L1 protein pentamers.
The number of L2 minor structural proteins is uncertain but there may be up to 72 copies of L2
incorporated into the capsid [16–19]. Twelve L1 pentamers map to the icosahedral 5-fold axes
(pentavalent capsomers), whereas the other 60 pentamers are located at the pseudo 6-fold axes
(hexavalent capsomers). The apical surface of each capsomer is comprised of the antigenic loops
(BC, DE, EF, FG and HI loops from each L1 protein) that connect eight antiparallel beta strands (BIDG
and CHEF). This conformation forms the common jellyroll structural motif [20,21]. An extension of
the L1 C-terminus, or C-terminal arm, links capsomers together and provides stability due to the
formation of disulfide bonds between 175.CYS and 428.CYS from two neighboring L1 proteins [22,23].
Since the HPV life cycle depends on the differentiation of keratinocytes, the restricted tropism
makes production and purification of high titer virus preparations for research problematic. Therefore,
alternative HPV production methods have been developed for molecular biology and structural
studies. Virus-like particles (VLPs) can be comprised of only the major structural protein (L1) or of
the major and minor capsid proteins (L1/L2) but are not infectious since they are devoid of viral
genome [24–26]. Pseudovirus (PsV) is comprised of both structural proteins, which are expressed
along with a plasmid so that a copy of the plasmid DNA can be packaged as a mock genome [27].
Quasiviruses (QV) assemble a structurally complete capsid and are infectious since they package a
copy of the cottontail rabbit papillomavirus genome (CRPV) [28]. All of these types of HPV capsids
preserve the main attributes of the native capsid structure and have been used successfully for vaccine
development and for studies of antigenicity, receptor usage, entry mechanisms and capsid structure.
Quaisivirus has been used for the HPV16 work presented here and is referred to throughout as HPV.
First generated from mice in 1996, H16.V5 (V5) and H16.U4 (U4) are two distinctive monoclonal
antibodies reactive to surface conformational epitopes on the intact HPV16 VLP [29]. V5 blocks the
serological reactivity of human sera with the corresponding capsids and neutralizes authentic HPV16
in vitro [30,31]. V5 has become an especially important tool in inhibition-based HPV serological assays
and is used extensively in major HPV vaccination trials. Mutational studies have suggested the FG
and HI surface loops contribute to the V5 antibody binding sites [20,32–34]. Previous studies with U4
have shown this antibody to be type-specific, in that U4 neutralizes pseudotype HPV16 capsids but
not authentic ones [20,31]. Further biological studies showed that U4 prevented virus binding to the
cell surface but not to the extracellular matrix (ECM), suggesting a competition with cell receptor [33].
HPV16 capsid and Fab molecules have been used to form complexes for structural solution using
3-dimensional (3D) reconstruction techniques [11,35,36]. We previously solved cryo-EM reconstructions
of HPV-V5 and HPV-U4 complexes with resolutions of 10–12 Å [11,12,36]. These modest resolution
maps verified that V5 binds to L1 loops at the apical surface of the capsomer and U4 binds to
the C-terminal arm of the L1 protein. The epitopes of the two Fabs were predicted from fitting of
homology models. The previous work also provided evidence for neutralization mechanisms of
super-stabilization and cross-linking for V5 and steric interference with cell attachment for U4.
Harnessing the revolutionary technology in cryo-EM image detection presented by direct
electron detectors (DED) and reconstruction software programs, we recently investigated HPV and
HPV-heparin complexes at near atomic resolution [37]. Besides identifying the heparin binding
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site around the five-fold vertex, this work specifically allowed us to define non-L1 densities in the
HPV capsid, which might be interpreted as putative L2 protein densities. Due to the technological
advance, atomic or near atomic resolution structures may correct or add to the information gained
from previous low resolution structures and illustrate the importance of solving high resolution
structures to be used to drive continuing research [38,39]. Here we present the near-atomic resolution
structures of HPV-V5 and HPV-U4 complexes at 4.7 Å and 5.8 Å resolutions, respectively. With these
high-resolution maps, the alpha carbon backbone of the Fab structure was built, the interaction
between Fab and capsid was identified and Fab-induced capsid conformational changes were tracked
for the first time. Specifically, the V5 stabilization mechanism was illustrated and the binding mode
of the Fab identified without ambiguity, thus defining the epitope on an atomic level. Importantly,
the epitopes identified here are based on structures built into the high-resolution density and the
ensuing accuracy allows these footprints to supersede those identified previously by fitting Fab
models into low resolution maps. Competition assays between V5 and U4 showed that binding of V5
prevents subsequent binding of U4, even though the V5 and U4 footprints do not overlap. We discuss
mechanisms of conformational change and steric collision induced by V5 binding. The binding site
of U4 was found to overlap with the recently determined heparin-binding site [37]. The preferential
binding of U4 around pentavalent capsomers and not hexavalent capsomers suggests a model by
which a capsid vertex may be selected during virus entry to interact with the host cell.
2. Materials and Methods
2.1. Preparation of Virus
HPV16 quasivirus containing L1 and L2 proteins and encapsidating a cottontail rabbit papillomavirus
genome (CRPV) having the Simian vacuolating virus 40 (SV40) origin of replication were prepared
as described previously [40–42]. Briefly, HPV16 sheLL plasmid (given by John Schiller, NIH) was
transfected with linear CRPV/SV40ori DNA into 293TT cells. The preparation proceeded as described
previously [43,44]. HPV16 matured overnight, pelleted by centrifugation, resuspended in 1 M NaCl
0.2 M Tris, pH 7.4. After CsCl gradient ultracentrifugation, the lower band was collected, concentrated
and dialyzed against phosphate buffered saline (PBS), as described [11,12]. Concentrated HPV16 particles
were applied to Formavar-coated copper grids, stained with 2% phosphotungstic acid (PTA) and observed
by transmission electron microscopy (TEM) on a JEOL JEM 1400 electron microscope (Tokyo, Japan).
2.2. Preparation of Antibody and Fabs
Monoclonal antibody (MAb) production has been described previously [29,40,45]. MAb were
purified from hybridoma supernatants using a protein A IgG purification kit (Pierce). Fab was digested
and purified from the MAb using a Fab preparation kit (Pierce). Briefly, ~2 mg of each MAb was
loaded over a Zeba desalting spin column (Pierce). Separately, V5 and U4 MAb were incubated with
cysteine and papain at 37 ◦C for 3 h with end-over-end mixing. After this incubation, the sample was
purified on a protein A column and BS was used to elute the Fabs. The purity of the Fab was assessed
by absence of the Fc portion and the integrity of the Fab was determined by performing an ELISA
(enzyme-linked immunosorbent assay). Antibody and Fab protein concentrations were estimated by
taking optical density readings using absorbance spectrometry at a wavelength of 280 nm.
2.3. Cryo-Electron Microscopy
HPV16 was incubated with an excess of 4 Fab molecules for each of the predicted 360 binding sites
per capsid for 1 h at room temperature and concentrated to 1.2 mg/mL in PBS buffer. A volume of 3 µL
of virus-Fab complex was applied to Quantifoil holey carbon support grids (Quantifoil, Jena, Germany),
blotted and plunged into liquid ethane using a Cryoplunge 3 (Gatan, Pleasanton, CA, USA). Low-dose
micrographs were recorded using an FEI Polara G2 microscope operating at 300 kV. Images were collected
under the control of the E Pluribus Unum software program (EPU) using an FEI Falcon 2 direct electron
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detector with 1.4× post-column magnification and a nominal magnifications of 59,000× for HPV-V5
and 93,000× for HPV-U4, yielding calibrated pixel sizes at the sample of 1.75 Å and 1.15 Å, respectively.
Defocus ranges of 0.65–3.56 µm and 0.26–5.18 µm (Table 1) were measured for micrographs of HPV-V5 and
HPV-U4, respectively. REgularized LIkelihood OptimizatioN (RELION), AUTO3DEM and Electron
Micrograph ANaly-sis (EMAN2) program software suites were used for image processing and 3D
reconstructions [46–48].
Table 1. Cryo-EM image reconstruction data.
HPV-V5 HPV-U4
Number of Micrographs 1899 8899
Defocus level range (µm) 0.65–3.56 0.26–5.18
Number of Particles Selected from Micrograph 27,095 58,571
Number of Particles Selected for reconstruction 17,612 35,151
Final Resolution 4.7 5.8
2.4. Image Processing
Whole frame alignment was carried out using MotionCorr to account for stage drift [49].
The microscope contrast transfer function parameters were estimated for each micrograph using
ctffind4 [50]. Semiautomatic particle selection was performed using EMAN2 e2boxer.py to obtain the
particle coordinates, followed by particle extraction, linearization, normalization, apodization and 3-D
reconstruction of the images using auto3DEM 4.05 following the gold standard method of initiating
the process by splitting the data set into two independently-refined halves [46,51]. The sharpening
of the high resolution information was performed using EMBFACTOR [52,53]. Reported resolutions
were estimated according to the gold-standard Fourier shell correlation (FSC) = 0.143 criterion [54].
2.5. Model Building
The atomic model of the HPV16 L1 capsomer with the C-terminal arm truncated (PDB ID, 3OAE;
residues 20–403, 438–474) was fitted as a rigid body and propagated to fill an asymmetric unit of the
HPV16 capsid (PDB ID, 3J6R; residues 9–486) [55,56]. This asymmetric unit was used as a guideline
during model building [57], which proceeded de novo to place the missing C-terminal arm residues
404–437 and the N- and C-termini residues using the software program Coot [58]. Building of the
Fab structure was initiated by fitting a previously published variable domain model (V5 PDB ID 3J7E;
U4 PDB ID 3J6R) and the constant domain of 3GK8 using Coot [12,35,58]. Icosahedral symmetry was
applied to the refined asymmetric unit model including Fabs to generate the capsid-Fab complex
through Situs [59,60]. The capsid atomic model was then further refined iteratively using Phenix Real
Space Refinement program [61]. At each iteration, the best model was visually inspected in Coot and
adjusted manually accordingly to the best fit into the density and guided by torsion restraints, planar
peptide restraints and Ramachandran restraints. The quality of the final model was evaluated by
Molprobity (http://molprobity.biochem.duke.edu/) [62] (Tables 2 and 3). Contacts between the fitted
Fab and L1 protein structures were identified using UCSF Chimera with the criteria for van der Waals
(VDW) overlap distances set at −0.4 and 0.0 Å. Clashes between atoms were defined by any overlap of
0.6 Å or more [56].
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Table 2. Molprobity Statistics for HPV-V5.
Asymmetric Unit Six Subunits (L1 Protein) Cryo-Electron Microscopy (Cryo-EM) Model 3732 Residues at4.7 Å Resolution after Phenix Global Refinement
Density agreement Correlation Coefficient 0.85






Molprobity Score 2.51% (47nd percentile)
Cβ deviations 0.03%
Bad backbone 0.06%
Bad backbone angles 0.19%
* Clash score is the number of serious steric overlaps (>0.4 Å) per 1000 atoms.
Table 3. Molprobity Statistics for HPV-U4.
Asymmetric Unit Six Subunits (L1 Protein) Cryo-EM Model 3004 Residues at 5.8 Å Resolution after
Phenix Global Refinement
Density agreement Correlation Coefficient 0.82






Molprobity Score 2.69% (47nd percentile)
Cβ deviations 0.13%
Bad backbone 0.18%
Bad backbone angles 0.34%
* Clash score is the number of serious steric overlaps (>0.4 Å) per 1000 atoms.
2.6. Magnitude Ratio Calculation
Our native HPV16 map (EMDB-6620) was subtracted from the HPV-V5 and HPV-U4 complex
maps separately to identify difference density corresponding to V5 Fab and U4 Fab, respectively.
The difference maps were used as a guide to mask the Fab densities from HPV-Fab complex maps
for comparison of their average density with that of the capsid (density/pixel for the whole box size)
using the mask function of UCSF Chimera. The average density was further divided by the volume
of capsid and Fab densities, respectively, to obtain a final density magnitude value. To compare
the hexavalent V5 Fab and pentavalent V5 Fab, their respective densities were isolated using the
segmentation function of UCSF Chimera followed by the method described above.
2.7. Competition Capture ELISAs
Purified mAbs V5 or U4 were bound to the wells of a 96-well microtiter plate in 50 µL 50 mM
Sodium Carbonate pH 9.6 and incubated overnight at 4 ◦C. The wells were washed with wash buffer
(PBS supplemented with 0.05% Tween-20) following the overnight incubation and in between all
subsequent additions to the wells. Blocking buffer (5% non-fat milk) was added to the wells for one
hour and during the one hour block, HPV (quasivirus) (500 ng/well) and serial dilutions of mAb were
incubated together in blocking buffer. Following the removal of the blocking buffer, HPV-mAb complex
was added to the wells and incubated for 30 min. We could not assess capture of the complex directly
by probing for the complexed mAb because it was titrated and low concentrations of the complex
mAb would inevitably result in low levels of detection. Capture of the HPV-U4 complex was therefore
determined indirectly through the binding of a V5 IgA class/isotype switch-variant (10 µg/mL) which
differs phenotypically from the original mAb clone due to rearrangements in the heavy chain genes and
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an alkaline-phosphatase (AP) conjugated anti-IgA secondary antibody (Southern Biotech). AP signal
was developed with p-Nitrophenyl Phosphate (Sigma, St. Louis, MO, USA). Due to the fact that the
V5 IgA mAb shares the same epitope as the original V5 clone (IgG2b), we could not directly use
the V5 IgA mAb as a probe for detection of captured HPV-V5. Instead, we assessed HPV capture by
probing for both V5 isotypes.
Cryo-EM maps for the HPV-V5 and HPV-U4 complexes are deposited in the EM database
(www.emdatabank.org/) with accession numbers EMD-8243 and EMD-7136, respectively. Coordinates
for each atomic model of the asymmetric unit of the two complexes with V5 and U4 Fab molecules
were deposited in PDB 6BT3 and PDB 6BSP, respectively.
3. Results
3.1. Cryo-EM Reconstructions of HPV-V5 Fab and HPV-U4 Fab Complexes
The purified V5 Fab molecules formed stable complexes with HPV16 virions. Cryo-EM images of
frozen hydrated complexes revealed a seemingly homogenous population of ~700 Å diameter spheres
labeled uniformly with V5 Fab branch-like densities (Figure 1A). No empty capsids were observed,
although some unbound V5 Fab was apparent in the background due to the incubation of Fab in
excess of binding sites. For the HPV-U4 complexes, binding with an excess of U4 Fab molecules did
not change the capsid appearance significantly but resulted in a slightly blurred capsid circumference
(Figure 1B). The size of HPV-U4 complex appeared about the same as the HPV16 unbound particles
with a diameter of ~580, suggesting no obvious gross conformational changes and indicating the U4 is
bound into the canyon region.
Using the gold standard method of image reconstruction, the structures of HPV-V5 and HPV-U4
complexes were determined to resolutions of ~4.7 Å and ~5.8 Å, respectively, where the Fourier shell
correlation (FSC) dropped below 0.143 (Figure 2). However, when the V5 Fab densities for V5 were
excluded from the calculations, the local resolution of capsid reached ~4.3 Å (Figure 2), which was
comparable to our recent HPV16 reconstruction [37].
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Figure 1. Cryo-electron microscopy (Cryo-EM) reconstructions of HPV16-V5 and HPV16-U4.
Representative regions of cryo-EM micrographs of the HP 16-V5 (A) and HPV16-U4 (B) virus-fab
complexes; (C,D) the surface re dered 3D maps of HPV16-V5 (C) and HPV16-U4 (D) were radially
colored according to the distance from the center (c or key in Ångstroms) of the capsid and surface
rendered at 1σ; (E,F) the zoom-in view of the five-fol vertex (black pent gon) of V5 (E) and U4 (F) maps
shows the density corresponding to bound Fab molecules (dark blue); (G,H) the central sections through the
cryo-EM density maps show the quality of the reconstructions. Capsids were cut vertically through the two-,
three- and five-fold icosahedral symmetry axes (black lines), with the central two-fold axis appearing at the
12 o’clock position; (I) the V5 Fab densities associated with the hexavalent (black hexagon) and pentavalent
(black pentagon) capsomers showed different magnitudes. The magnitude ratio between hexavalent Fab
(Hexa-V5) and pentavalent Fab (Penta-V5) was measured as 1:0.4.
The bound V5 Fab moieties could be recognized easily as spikes on the surface of the PV cryo-EM
density map and occupied nearly all binding sites on the capsid (Figure 1C,E). However, there was an
apparent density difference between Fabs occupying hexavalent capsomer and pentavalent capsomers,
as has been noted previously [35,36] (Figure 1E,I). The pentavalent Fab density was not continuous
and the magnitude was significantly weaker (60%) than the hexavalent Fab density.
In the HPV-U4 complex map, density regions corresponding to the U4 Fab were observed around
the pentavalent capsomers at each five-fold vertex of the capsid (Figure 1D) as has been seen previously
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at lower resolution [12]. Fab density was located in each of the five canyons formed between pairs of
hexavalent capsomers and the pentavalent capsomer, resulting in a total of 60 Fab binding sites per
capsid. However, as the U4 Fab density was 70% of the HPV16 capsid, we estimate that on average
only 42 of the 60 sites per capsid were occupied by U4 Fabs. Central sections through the density maps
illustrated the high quality of the reconstructions and identified the location of Fab densities according
to the 2-, 3- and 5-fold symmetry (Figure 1G,H).
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3.2. Building the V5 Fab and L1 Protein Structures into the High-Resolution Cryo-E aps
The predicted eb based antibody model (WAM) structure model of the Fab variable domain was
combined with the constant domain of a published homologous crystal structure (PDB ID 3GK8) [63]
and fit into the corresponding cryo-EM density. The Fab model was built by stepping through the
fitted structure and correcting all sections and discernable side chains that were out of density. The L1
proteins inside the hexavalent and pentavalent capsomer were built independently using the crystal
structure (PDB ID 3OAE) as a guide and correcting and adding residues that could be uniquely assigned
to density. Due to steric limitations, only four V5 Fabs were included in the asymmetric unit, which was
co prised of five hexavalent L1 proteins and one pentavalent L1 protein (Figure 3A). Refinement of
the asymmetric unit was followed by global refinement in the context of the entire capsid. Verification
of the resulting structure was evaluated with Molprobity (Table 2) (Methods).
Due to the pseudo-two-fold symmetry of the Fab molecule, the V5 Fab could be fitted with
the heavy chain facing outwards away from the capsomer center or with the light chain facing
outwards (Figure 3A,B). The V5 molecule structure was built separately in both possible binding modes.
Previously, based on a poorer resolution map, the proposed model for V5 binding was in the heavy
chain-outwards mode of binding [11]. This mode was confirmed here using the new near-atomic
model of V5 Fab (Figure 3D–G). Examples that verify the orientation of Fab include the side chain of
59H.TRP, which fit better in the heavy chain outwards structure, since the light chain outward mode
would place a 59L.TYR poorly into the same density (Figure 3D,F). A similar result was also observed
in the better fit of H74-H77 compared to a poorer fit of L74-H77 in the same density (Figure 3E,G).
The structure of U4 Fab was produced using the same method as for V5. The L1 asymmetric
unit structure produced from the HPV-V5 complex was used to initiate building L1 in the HPV-U4
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complex. Since U4 Fab only bound in the canyon around the pentavalent capsomers, the asymmetric
unit for HPV-U4 included six L1 proteins and one U4 Fab. This unit was used to generate the whole
capsid-U4 structure for Phenix global refinement. U4 Fab was built with the heavy chain relative to the
light chain (heavy chain followed by the light chain) around the five-fold vertex in a counterclockwise
direction (Figure 4) [12]. The Molprobity score was also used to evaluate U4 model building (Table 3).
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Figure 3. V5 Fab and L1 protein structures. (A) The asymmetric unit used for refinement includes six
L1 proteins (black wire), five L1 from the hexavalent (black hexagon) and one L1 from the pentavalent
(black pentagon) capsomers and four V5 fabs with heavy chain (blue) and light chain (red) shown in
wire. V5 Fab was built in both possible orientations; (B) with heavy chain (blue ribbon) facing outward
from the center of the capsomer and (C) with he light (red ribbon) chain facing outwards. Cl se up
views show the fit of specific residues that aided in the identificatio f the correct binding mode;
(D) the side chain of 59H.TRP fitted well into the density of the heavy chain outwar s build; however
light chain outward placed 59L.TYR into the same density and a poor fit; (F) similar results were also
observed for H74-H77 residue sequence in heavy chain facing out mode (E) compared to the light chain
facing out mode (G) of unfilled density.
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Figure 4. U4 Fab bound the HPV16 capsid in a heavy chain (blue) followed by the light chain (red)
ode around each five-fold vertex in a counterclockwise direction (blue arrow). The distance between
the neighboring heavy chain C-termini (yellow) at the constant domain was measured to discriminate
between monovalent and bivalent binding of U4 Mab. The pseudo-two-fold axis of the Fab (black stick)
is indicated and the angle between neighboring axes was 45 degrees.
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3.3. V5 Binding Induces Order to Capsomer Loops and Improves Resolution Significantly
The mass axis of L1 proteins in pentavalent and hexavalent capsomers in the HPV and the
HPV-Fab complex maps were determined (Figure 5A,B) to track potential rotational and translational
movements of L1 proteins after Fab binding (Table 4). Binding with V5 induced the L1 protein to
rotate only slightly outwards (0.3 degrees) from the center of the capsomer; however, L1 moved
as a rigid body away from the capsomer center 2.5 Å. The arrangement of surface loops remained
nearly the same and only slight translational movements as a rigid body were measured (Figure 5D).
Superimposition of the pentavalent and hexavalent capsomer structures from the HPV-V5 and HPV16
reconstructions were essentially the same with statistically negligible root-mean-square deviation of
atomic positions (RMSD) (0.58 Å and 0.66 Å, respectively for hexavalent and pentavalent capsomers).
After masking out the Fab densities from the map, the capsid shell resolution was nearly the same
(4.3 Å) (Figure 2) as our previously solved HPV16 map [37]. However, the local resolution of the
pentavalent and hexavalent capsomers was significantly improved, which indicates structural ordering
of the loops was induced by binding with Fab molecules. Especially for the apical capsomer surface,
compared to HPV virions, both pentavalent and hexavalent complex capsomers had nearly 2 to 3 Å
better resolution after Fab binding (Figure 6). Compared to the native HPV16 map, there are some
regions of lower resolution in the complex (Figure 6A, blue arrow) where FG and HI loops are located.
The only capsid location that showed no change after Fab binding was at the rim of the capsomer, at the
location of the EF and BC loops, where the local resolution stayed the same after binding with Fab.
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Figure 5. Fab binding induces conformational changes to the HPV16 capsid. (A) The L1 proteins in the
pentavalent (labeled 1–5) and hexavalent (labeled a–e) capsomers are colored coded individually as
pink, cyan red, yellow and green with the mass axis (black) depicted for each L1; (B,C) the mass axis
arrangement in HPV (PDB ID: 5KEP) (red) is superimposed with those of HPV-V5 (Blue) and HPV-U4
(green) (D) (blue) and those from the HPV-U4 (E) (cyan) maps, which illustrates the movement of
surface loops on the capsomers (37).
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the pentavalent capsomer, whereas the angle between two neighboring Fabs was 45°. These 
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the Fc portion of an intact U4 antibody would allow the variable regions to bind two different 
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Figure 6. Surface rendered maps of HPV (EMDB-6620) (A) and HPV-V5 (B) are colored according to
local resolution (color key 3.8–6.5 Å resolution) and zoomed to show hexavalent (black hexagon) and
pentavalent (pentagon) capsomers (37). Notably the region of the FG and HI loops (black arrow) is
quite flexible prior to Fab binding as attested by the low resolution. After Fab binding the entire apical
capsomer surface has been stabilized and has a local resolution of ~3.8 Å.
Table 4. The conformational change of each L1 protein (see Figure 5A for L1 labels) includes both
rotational (degree) and translational (Angstrom) movements.
HPV-V5 Pentavalent Capsomer L1 Hexavalent Capsomer L1
#1 #2 #3 #4 #5 #a #b #c #d #e
Angl ◦) 0.21 0.22 0.22 0.21 0.55 0.20 0 4 0 2 0.48 0.27
Distance (Å) 2.99 2.28 0.99 1.61 2.51 1.57 1.50 2.45 2.57 2.25
HPV-U4 Pentavalent Capsomer L1 Hexavalent Capsomer L1
#1 #2 #3 #4 #5 #a #b #c #d #e
Angle (◦) 0.96 0.96 0.96 0.96 0.97 1.39 1.00 0.64 0.93 1.37
Distance (Å) 1.98 1.98 1.99 2.00 3.45 1.25 1.68 2.36 2.86 1.82
3.4. U4 Fab Binding Suggests MAbs Bind Monovalently
The newly built models of U4 Fab and the L1 protein were used to evaluate the binding mode
for the entire bipartite antibody molecule. For an antibody to be able to bind bivalently, the distance
between the C-terminal Cα atoms of adjacent heavy chains is typically in the range of 25–29 Å [64–66].
The angle between two Fab arms in a typical IgG antibody can reach 120◦ [67,68]. The distance
between Fabs in the HPV-U4 complex was 96 Å between two neighboring U4 Fabs bound around the
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pentavalent capsomer, whereas the angle between two neighboring Fabs was 45◦. These distances
and angles are consistent with monovalent binding for MAb U4 (Figure 4), which suggests the Fc
portion of an intact U4 antibody would allow the variable regions to bind two different capsids,
thereby crosslinking capsids as a potential neutralization mechanism.
3.5. Assessing Capsid Conformational Changes Initiated by U4 Binding
The U4 Fab was observed only in the canyon between hexavalent and pentavalent capsomers
with most of its body inside of the inter-capsomeric space (Figure 1F). The radial density plots of
the density maps indicated no significant difference in diameter between HPV16 and the HPV-U4
complex map (Figure 7) suggesting that U4 Fab binding did not trigger a change in the overall size of
the capsid. The mass axis of L1 proteins in pentavalent and hexavalent capsomers in the HPV and the
HPV-U4 Fab complex maps indicated negligible rotational and translational movements of L1 protein
as a rigid body after U4 binding. The measurement of L1 protein rotation away from the capsomer
center was ~1◦, with a 2 Å movement from the center (Table 4). The measurements for L1 protein
differences in hexavalent and pentavalent capsomers were approximately the same. The RMSD value
of L1 proteins in hexavalent and pentavalent capsomers were less than 1 Å when superimposed with
the capsomer structures of native HPV16 (EMDB-6620). Thus, at this resolution the measurements are
below what can reasonably be considered actual movement induced by Fab binding.
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142.ASP, 143.ASN) loops. All of the binding sites were exposed and located at the topmost apical 
surface of the capsomer (Figure 8). The binding site for the U4 Fab was located deep in the canyon 
and significantly different than reported previously [12]. Specifically the U4 epitope was comprised 
of residues from the C-terminal arm of a hexavalent L1 protein (431.HIS and 437.LYS) located 
adjacent to a pentavalent capsomer and three residues from the EF loop (180.VAL, 179ALA, 
176THR) of the pentavalent L1 at the edge of the capsomer crown (Figure 8). The V5 and U4 
antibody binding sites did not interfere or overlap with each other. Since a total of 14 residues 
participated in the binding with V5 compared with five residues for U4, the interaction between 
HPV16 capsid and V5 was predicted to be stronger than the interaction with U4. 
Figure 7. Radial density distributions from center of the map to the edge of the capsid for HPV16
(EMDB-6620) (black), HPV16-V5 (red) and HPV16-U4 (blue) maps. The two dotted lines designate the
capsid range.
3.6. V5 and U4 Bind to Different Sites
Atomic models of L1, V5 and U4 fitted into the cryo-EM density were used to define the antibody
binding sites (Table 5). The epitope of V5 was distributed among BC, DE, EF, FG and HI loops
contributed by two neighboring L1 proteins within one capsomer. As the major contributor to
residues in the binding site, the FG loop provided five residues (267.VAL, 278.LYS, 280.SER, 285.ASN),
whereas three residues mapped to the HI (348.ILE, 357.ASN, 358.THR) and DE (139.ALA, 142.ASP,
143.ASN) loops. All of the binding sites were exposed and located at the topmost apical surface of the
capsomer (Figure 8). The binding site for the U4 Fab was located deep in the canyon and significantly
different than reported previously [12]. Specifically the U4 epitope was comprised of residues from
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the C-terminal arm of a hexavalent L1 protein (431.HIS and 437.LYS) located adjacent to a pentavalent
capsomer and three residues from the EF loop (180.VAL, 179ALA, 176THR) of the pentavalent L1 at
the edge of the capsomer crown (Figure 8). The V5 and U4 antibody binding sites did not interfere or
overlap with each other. Since a total of 14 residues participated in the binding with V5 compared
with five residues for U4, the interaction between HPV16 capsid and V5 was predicted to be stronger
than the interaction with U4.Viruses 2017, 9, 374  13 of 20 
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Figure 8. Zoomed view of a surface rendered HPV16 capsid (grey) map illustrates the epitope of V5
(blue) and U4 (cyan) on the surface. The V5 epitope is shown mapped to the hexavalent (hexagon)
capsomer, whereas the U4 epitope lies between the hexavalent and pentavalent (pentagon) capsomers.
Table 5. Residues that comprise the conformational epitopes of V5 and U4. Residues from neighboring
L1 protein was designated by X′.
L1 Protein Surface Loop and C-Terminal Arm (C-Ter) V5 Fab HeavyChain Outwards
U4 Fab eavy Chain
Count Clockwise
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3.7. V5/U4 mAb Competition Is Sequentially Dependent
Although the V5 and U4 footprints do not overlap, V5 binding induces conformational changes in
the form of ordering flexible loops comprising the capsomers. To assess further the V5 and U4 epitopes
biochemically and the consequences of binding, we performed a competition assay with the V5 and
U4 mAbs. Competition was assessed by a capture ELISA in which U4 was used to capture HPV-V5
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complex and V5 was used to capture HPV-U4 complex (Figure 9A). HPV-U4 was successfully captured
by V5 mAb, confirming the non-overlapping nature of the two epitopes (Figure 9B). When the U4 mAb
was used to capture the HPV-V5 complex, the amount of captured complex was diminished at the
highest concentrations of V5 mAb (Figure 9C). The detection of captured HPV was only recovered at
lowest dilutions of V5 mAb to 0.1 µg/mL.Viruses 2017, 9, 374  14 of 20 
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The percentage of captured HPV detected by isotype switch-variant V5 IgA  remains the same 
regardless of antibody concentration, while it is apparent that the amount of U4 detected by the 
anti-IgG2a secondary mAb titrates ; (C) capture of the HPV-V5 complex by the U4 mAb  
was ablated at high concentrations of V5. The mAb interference and the inability to capture HPV is 
also evident by the failure to directly detect V5 mAb ; (D) schematic of pentavalent and 
hexavalent L1 pentamers (blue) demonstrating steric hindrance of V5 mAb (black) with the U4 mAb 
(purple). Preliminary binding of the V5 mab to the vertices of hexavalent capsomers creates an 
“umbrella” over the U4 epitope and thus prevents the secondary binding of U4 mAb. 
4. Discussion 
4.1. The Near-Atomic Resolution Map Allowed Building of the 50 kDa Fab Structure 
The high resolution achieved for the complex maps allowed us to build the structures of the L1 
protein, including the C-terminal arm and the relatively small 50 kDa V5 Fab molecule. Here we 
have overcome the difficulty of reconstructing a small molecule by incubating virus particles 
together with the small Fab molecules and solving the structure of the icosahedrally symmetric 
complex at high resolution. The structure of Fab was then built into the corresponding density. Thus, 
the large virus acted as a symmetric scaffold presenting the smaller Fab molecules for structural 
solution. This approach suggests a general use for symmetric virus capsids serving as a platform for 
Figure 9. U4 and V5 bind different L1 epitopes but likely steric hindrance prevents U4 capture in ELISA.
Two different HPV preparations were assayed and the mean of three independent assays, each with
duplicates, are shown. Captured HPV-mAb complex is graphed as a percentage of maximum HPV
capture in the absence of mAb. Parentheses ( ) in the figure legends denote the sequential additions
of mAb or HPV-mAb complex and the mAb isotype (A) Schematic of 16.V5 and 16.U4 competition
capture ELISAs. The capture antibody was bound to the well of a microtiter plate and complexed
HPV-mAb was added in attempt to bind and immobilize the complex; (B) high concentrations of U4
did not impede capture of the HPV16-U4 complex by the V5 mAb. The percentage of captured HPV
detected by isotype switch-variant V5 IgA
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the large virus acted as a symmetric scaffold presenting the smaller Fab molecules for structural 
solution. This approach suggests a general use for symmetric virus capsids serving as a platform for 
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hexavalent L1 pentamers (blue) demonstrating steric hindrance of V5 mAb (black) with the U4 mAb 
(purple). Preliminary binding of the V5 mab to the vertices of hexavalent capsomers creates an 
“umbrella” over the U4 epitope and thus prevents the secondary binding of U4 mAb. 
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4. Discussion
4.1. The Near-Atomic Resolution Map Allowed Building of the 50 kDa Fab Structure
The high resolution achieved for the complex maps allowed us to build the structures of the
L1 protein, including the C-terminal arm and the relatively small 50 kDa V5 Fab molecule. Here we
have overcome the difficulty of reconstructing a small molecule by incubating virus particles together
with the small Fab molecules and solving the structure of the icosahedrally symmetric complex at
high resolution. The structure of Fab was then built into the corresponding density. Thus, the large
virus acted as a symmetric scaffold presenting the smaller Fab molecules for structural solution.
This approach suggests a general use for symmetric virus capsids serving as a platform for solving the
structure of small bound proteins and allows us to solve Fab structures without crystallography.
4.2. V5 Neutralizes by Stabilization
Our previous results suggested a super-stabilization neutralization mechanism for V5 based on
the interpretations developed from a WAM model of V5 and a 10 Å resolution complex map [35].
The new higher resolution map presented here allowed building of both V5 and HPV16 L1 protein.
This improvement allowed us to measure potential movements within the capsid that might have
been induced by V5 binding. The small magnitude of the measurements could not be interpreted
as movement of the L1 protein since they were well below the level of detection at this resolution
(Figure 5). However, stabilization induced by Fab binding was observed readily as the significantly
improved resolution of the capsid (Figure 6), which indicated less flexibility of the surface loops was
possible after an interaction with V5. The stabilization of capsid likely inhibits conformational changes
that are known to be essential for virus host entry and infection (3–9) [69,70].
4.3. V5 Preferentially Interacts with the Hexavalent Capsomer
Due to the steric hindrance between V5 binding sites on adjacent hexavalent and pentavalent
capsomers, only one V5 Fab can bind in either position [11,35]. However, occupation of the hexavalent
versus pentavalent site is not split evenly. Upon measuring the density magnitude ratio (pentavalent
Fab/hexavalent Fab = 40%) (Figure 1I), V5 was found to bind preferentially to the hexavalent L1
protein binding site. The quasi-equivalence of the T = 7 icosahedral capsid and previous studies have
predicted structural differences between the L1 molecules occupying hexavalent and pentavalent
capsomers [35,36]. The residues of the V5 epitope were found here to be distributed differently
in the pentavalent capsomer than the hexavalent capsomer due to the different L1 environments.
Thus, the preferential binding of V5 for the hexavalent capsomers effectively leaves the pentavalent
capsomers free to interact with host proteins. Previous biological studies showed that V5 did not
prevent attachment of capsids to the cell surface but inhibited the internalization of cell surface-bound
capsids [33]. Thus, the binding pattern of V5 suggests that HPV16 likely binds to the cell surface via
pentavalent capsomer interactions to initiate an infection.
4.4. U4 Blocks the Accessibility of Pentavalent Capsomer Sites
Based on previous biological studies, binding with U4 directly interferes with the virus attachment
to the cell surface, as shown by the inability of U4 to neutralize the virus post-attachment [33].
This phenomenon suggested the HPV16 capsid attaches to the cell surface receptor near the U4 binding
site in the canyon around pentavalent capsomers. This model is consistent with our recent work
that identified the site of heparin binding [37]. As a primary cell receptor for HPV16, the heparin
molecules were located around the pentavalent capsomer near the canyon in between the neighboring
EF and BC loops. Two of the five residues in the epitope of U4 overlapped with the known heparin
binding site. Thus, even though the geometry of binding might allow intact U4 antibody to crosslink
capsids, we propose that direct interference with receptor binding and blocking the accessibility of the
canyon are the main neutralization mechanisms for U4.
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4.5. The Conformational Epitopes of V5 and U4 Were Identified Using the High-Resolution Maps
Through previous immunological and structural studies, the epitopes of V5 and U4 were predicted
as multiple loops with participation from different copies of the L1 protein; however, these previous
epitopes were predicted based on fitting of homology models into the more globular envelope of
poorer resolution maps. Here we identified the epitopes of both V5 and U4 from the building directly
into near-atomic resolution maps. Thus, here we present the new, accurate epitopes of V5 and U4,
which supplant the predicted ones presented previously. Fewer residues were found in the epitope
of V5 than previously predicted as only nine residues were assigned to the new epitope. However,
the epitope of U4 was significantly different from that previously predicted from a poorer resolution map.
The C-terminal arm from one hexavalent protein and the EF loop from a pentavalent L1 protein
contributed to the binding with U4, which bridged the two neighboring proteins.
In our recent work with the 4.3 Å resolution map of HPV16, the putative L2 protein density
was found to occupy the outer side wall of the capsomer, with some minor portions at both surface
and the base. Even though U4 was raised against L1-only capsids, the U4 footprint overlaps the
position of L2 density (Figure 10), suggesting that regions of L2 protein are buried when U4 is bound
to the capsid. This possibility may provide another mechanism for U4 neutralization by stabilization
or sterically occluding regions of L2 protein necessary for entry. Thus, bound U4 might inhibit the
exposure of the L2 N-terminus for furin cleavage or other essential L2 related events required during
endocytosis [5,6,10–13].
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Figure 10. U4 may interact with the minor structural protein, L2. (A) The U4 Fab structure (heavy 
and light chain, blue and red, respectively) was superimposed onto putative L2 density identified 
previously (green) and the HPV16 capsid (grey mesh) (EMDB-6620) (37). The pentavalent capsomer 
is indicated in black pentagon. The zoomed view (B) shows the interface of the U4 variable domain 
with putative L2 density (green). 
4.6. The V5/U4 Conformational Epitopes Are Non-Overlapping but V5 Outcompetes U4 
Competition capture ELISAs confirmed that V5 and U4 bind two distinct regions of the viral 
capsid as V5 captured 100% of HPV particles complexed with U4. Although these antibodies bind 
disparate epitopes, the interference observed when HPV-V5 complexes were tested for capture by 
U4 mAb suggests a steric collision of intact antibody. The possible steric hindrance by the V5 Fc may 
be due to the binding angle of the V5 Fab at 47° Saturating concentrations of V5 could therefore 
create an “umbrella” over the capsid canyons, rendering the U4 epitope impenetrable to U4 mAb 
and subsequent capture of the HPV-V5 complex impossible (Figure 10D). The surface-saturating 
effects of V5 leads us to conclude that U4 binding in the canyons of pentavalent capsomers is 
hindered by the steric blockade of the V5 Fc when sufficient saturation of the capsid has taken place. 
The opposite effect is not possible because U4 binds deep into the canyon and cannot occlude the 
more apically positioned V5 binding site. 
When HPV was incubated with low ratios of V5, U4 was also able to bind to the capsid, 
indicating that binding of V5 is not inducing conformational changes that affect subsequent U4 
binding. However, we cannot rule out that higher V5:virus ratios might lead to global capsid 
changes that do alter the U4 binding site. We have observed in our previous V5 map and the near 
atomic resolution map presented in this paper that V5 binding induces hyper-stabilization of the 
capsid. V5 Fab binding was shown to result in more ordered density of the L1 C-terminal arm, 
suggesting that V5 functionally inhibits capsid flexibility and stabilizes the C-terminus [35], which is 
the site of U4 binding. V5-induced stabilization of the C-terminal arm therefore might have the 
potential to modify the U4 epitope but only when most or all of the V5 binding sites are occupied. 
The extent of capsid stabilization positively correlates with the number of bound V5 Fabs suggesting 
that if V5 inhibits U4 binding through conformational changes it may only be able to do so under 
saturating conditions of V5. 
Figure 10. U4 may interact with the minor structural protein, L2. (A) The U4 Fab structure (heavy
and light chain, blue and red, respectively) was superimposed onto putative L2 density identified
previously (green) and the HPV16 capsid (grey mesh) (EMDB-6620) (37). The pentavalent capsomer is
indicated in black pentagon. The zoomed view (B) shows the interface of the U4 variable domain with
putative L2 density (green).
4.6. The V5/U4 Conformational Epitopes Are Non-Overlapping but V5 Outcompetes U4
Competition capture ELISAs confirmed that V5 and U4 bind two distinct regions of the viral
capsid as V5 captured 100% of HPV particles complexed with U4. Although these antibodies bind
disparate epitopes, the interference observed when HPV-V5 complexes were tested for capture by
U4 mAb suggests a steric collision of intact antibody. The possible steric hindrance by the V5 Fc
may be due to the binding angle of the V5 Fab at 47◦ Saturating concentrations of V5 could therefore
create an “umbrella” over the capsid canyons, rendering the U4 epitope impenetrable to U4 mAb and
subsequent capture of the HPV-V5 complex impossible (Figure 10D). The surface-saturating effects
of V5 leads us to conclude that U4 binding in the canyons of pentavalent capsomers is hindered by
the steric blockade of the V5 Fc when sufficient saturation of the capsid has taken place. The opposite
effect is not possible because U4 binds deep into the canyon and cannot occlude the more apically
positioned V5 binding site.
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When HPV was incubated with low ratios of V5, U4 was also able to bind to the capsid, indicating
that binding of V5 is not inducing conformational changes that affect subsequent U4 binding. However,
we cannot rule out that higher V5:virus ratios might lead to global capsid changes that do alter the U4
binding site. We have observed in our previous V5 map and the near atomic resolution map presented
in this paper that V5 binding induces hyper-stabilization of the capsid. V5 Fab binding was shown to
result in more ordered density of the L1 C-terminal arm, suggesting that V5 functionally inhibits capsid
flexibility and stabilizes the C-terminus [35], which is the site of U4 binding. V5-induced stabilization
of the C-terminal arm therefore might have the potential to modify the U4 epitope but only when
most or all of the V5 binding sites are occupied. The extent of capsid stabilization positively correlates
with the number of bound V5 Fabs suggesting that if V5 inhibits U4 binding through conformational
changes it may only be able to do so under saturating conditions of V5.
The data presented herein elucidate function of two critically important MAbs, particularly V5,
which have been used extensively in HPV vaccine development, quality control assays to define
VLP vaccine integrity during storage and preservation and immunogenicity. By taking advantage of
the technological advances in cryo-EM, we have solved the structures of HPV16-Fab complexes at
near-atomic resolution and thus for the first time, have been able to unambiguously define the epitopes
of V5 and U4. To clarify, the V5 and U4 antibody footprints presented in this work supersede any
of our previously reported epitopes based on fitting models into EM maps. Although this method
has been cutting edge, the cryo-EM resolution revolution has ushered in a new era offering structural
biologists new accuracy. This accuracy has afforded a more thorough investigation of the Fab-induced
stabilization mechanisms and has allowed us to learn more about mechanisms of neutralization in
addition to viral entry mechanisms. Specifically the V5 preferential binding of hexavalent capsomers
leaves the five folds vertices (pentavalent capsomers) open even during V5 saturating conditions,
which may be directly linked to the fact that V5 does not inhibit host cell attachment. Given that U4
binds exclusively to the pentavalent capsomers, the structure and function of the two antibodies is
consistent with an HPV entry model whereby the virus gains entry to the cell via initial interactions
mediated by residues that map to the pentavalent capsomers.
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